Cargando…

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

INTRODUCTION: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment-experienced patients unless there was prior use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahomed, Kairoonisha, Wallis, Carole L., Dunn, Liezl, Maharaj, Shavani, Maartens, Gary, Meintjes, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AOSIS 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433307/ https://www.ncbi.nlm.nih.gov/pubmed/32832110 http://dx.doi.org/10.4102/sajhivmed.v21i1.1062

Ejemplares similares

A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy
por: Cohe, Karen, et al.
Publicado: (2019)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023)

Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
por: Meintjes, Graeme, et al.
Publicado: (2015)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
por: Zhao, Ying, et al.
Publicado: (2021)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial
por: Griesel, Rulan, et al.
Publicado: (2021)

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases
por: Cevik, Muge, et al.
Publicado: (2020)

Southern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapy
por: Moorhouse, Michelle A., et al.
Publicado: (2018)

Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps
por: Murphy, Richard A., et al.
Publicado: (2017)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort study
por: Asare, Kwabena, et al.
Publicado: (2023)

Early severe morbidity and resource utilization in South African adults on antiretroviral therapy
por: de Cherif, Teresa K Smith, et al.
Publicado: (2009)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
por: Griesel, Rulan, et al.
Publicado: (2023)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Complications of Antiretroviral Therapy Initiation in Hospitalised Patients with HIV-Associated Tuberculosis
por: van der Plas, Helen, et al.
Publicado: (2013)

Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes
por: Moorhouse, Michelle, et al.
Publicado: (2019)

Risk of immune reconstitution inflammatory syndrome with integrase inhibitors versus other classes of antiretrovirals: a systematic review and meta-analysis of randomised trials
por: Zhao, Ying, et al.
Publicado: (2022)

Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy
por: Meintjes, Graeme, et al.
Publicado: (2015)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy
por: Nakaharai, Kazuhiko, et al.
Publicado: (2017)

Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study
por: Court, Richard, et al.
Publicado: (2014)

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa
por: Wallis, Carole L., et al.
Publicado: (2011)

A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre
por: van Hoving, Daniël Jacobus, et al.
Publicado: (2022)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)

Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV
por: Banda, Clifford G., et al.
Publicado: (2022)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
por: Maartens, Gary
Publicado: (2020)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Delays in switching patients onto second-line antiretroviral treatment at a public hospital in eThekwini, KwaZulu-Natal
por: Narainsamy, Denver, et al.
Publicado: (2017)

Response to second line antiretroviral therapy in India
por: Singh, Anup, et al.
Publicado: (2012)

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
por: Hauser, Anthony, et al.
Publicado: (2020)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Association of First-Line and Second-Line Antiretroviral Therapy Adherence
por: Ramadhani, Habib O., et al.
Publicado: (2014)

Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus
por: Hirigo, Agete Tadewos, et al.
Publicado: (2022)

Low-level viraemia despite emergence of dolutegravir-resistant variants
por: Botha, Johannes C., et al.
Publicado: (2022)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy
por: Calmy, Alexandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6s3rcrqqvkvavrrha2cjbqepak